Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2018 1
2021 2
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Systemic Immune Dysregulation in Early Breast Cancer Is Associated With Decreased Plasma Levels of Both Soluble Co-Inhibitory and Co-Stimulatory Immune Checkpoint Molecules.
Rapoport BL, Steel HC, Hlatshwayo N, Theron AJ, Meyer PWA, Nayler S, Benn CA, Smit T, Kwofie LLI, Heyman L, Anderson R. Rapoport BL, et al. Among authors: kwofie lli. Front Immunol. 2022 May 23;13:823842. doi: 10.3389/fimmu.2022.823842. eCollection 2022. Front Immunol. 2022. PMID: 35677046 Free PMC article.
Elevated Levels of Soluble CTLA-4, PD-1, PD-L1, LAG-3 and TIM-3 and Systemic Inflammatory Stress as Potential Contributors to Immune Suppression and Generalized Tumorigenesis in a Cohort of South African Xeroderma Pigmentosum Patients.
Kgokolo MCM, Anderson K, Siwele SC, Steel HC, Kwofie LLI, Sathekge MM, Meyer PWA, Rapoport BL, Anderson R. Kgokolo MCM, et al. Among authors: kwofie lli. Front Oncol. 2022 Feb 11;12:819790. doi: 10.3389/fonc.2022.819790. eCollection 2022. Front Oncol. 2022. PMID: 35223501 Free PMC article.
Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3.
Rapoport BL, Steel HC, Benn CA, Nayler S, Smit T, Heyman L, Theron AJ, Hlatshwayo N, Kwofie LLI, Meyer PWA, Anderson R. Rapoport BL, et al. Among authors: kwofie lli. Front Oncol. 2023 Mar 30;13:1097309. doi: 10.3389/fonc.2023.1097309. eCollection 2023. Front Oncol. 2023. PMID: 37064132 Free PMC article.
Evaluation of circulating soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) to predict risk profile, response to antimicrobial therapy, and development of complications in patients with chemotherapy-associated febrile neutropenia: a pilot study.
Kwofie L, Rapoport BL, Fickl H, Meyer PW, Rheeder P, Hlope H, Anderson R, Tintinger GR. Kwofie L, et al. Ann Hematol. 2012 Apr;91(4):605-11. doi: 10.1007/s00277-011-1339-4. Ann Hematol. 2012. PMID: 21976106